Equities Analysts Offer Predictions for ODTX FY2026 Earnings

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) – Equities researchers at HC Wainwright issued their FY2026 EPS estimates for Odyssey Therapeutics in a report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($6.20) for the year. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q4 2026 earnings at ($1.26) EPS, FY2027 earnings at ($5.14) EPS, FY2028 earnings at ($5.03) EPS, FY2029 earnings at ($5.22) EPS and FY2030 earnings at ($4.83) EPS.

A number of other brokerages have also weighed in on ODTX. Raymond James Financial assumed coverage on Odyssey Therapeutics in a research note on Thursday, October 8th. They set an “outperform” rating and a $42.00 price target on the stock. Weiss Ratings initiated coverage on Odyssey Therapeutics in a research report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. JPMorgan Chase & Co. upped their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, UBS Group began coverage on Odyssey Therapeutics in a research note on Monday, October 12th. They issued a “buy” rating and a $27.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Odyssey Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.67.

Odyssey Therapeutics Price Performance

ODTX stock opened at $19.15 on Tuesday. The stock has a 50 day moving average price of $21.08. The stock has a market cap of $920.35 million and a PE ratio of -2.83. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ODTX. Russell Investments Group Ltd. purchased a new stake in Odyssey Therapeutics during the third quarter worth approximately $28,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Odyssey Therapeutics in the second quarter worth $601,000. State Street Corp acquired a new stake in shares of Odyssey Therapeutics in the second quarter worth $1,477,000. Aberdeen Group plc increased its position in shares of Odyssey Therapeutics by 4.7% in the third quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock worth $3,839,000 after acquiring an additional 7,771 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Odyssey Therapeutics in the 2nd quarter valued at $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing medicines for inflammatory and autoimmune diseases. Its research centers on the immune system and biological pathways that may be targeted to address these conditions.

Founded in 2021, the company uses drug-discovery capabilities to identify and advance potential therapies. Its business is research and development rather than the sale of marketed medicines.

Odyssey is based in the United States.